EN DE
Watch Corbion NV for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Corbion NV (CRBN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Corbion NV stock €16.71, price €26.84, that is 37.7% below the price, quality 61 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials NL · ISIN NL0010583399

CN Corbion NV logo Broad data Nov 8, 2026

Corbion NV

CRBN · AS
Solid, but very expensive

Our calculation puts a fair price 38% below what the stock costs today.

Quality 61/100
Low debt
Generates free cash flow
2.4% dividend yield · Sustainable
Upbeat coverage
Broad data
Mixed Growth (revenue YoY −1.6 %/yr in EUR)
Thin margins · 5.0% net margin (TTM)
Mixed vs. peers (8/15)
Fair value €16.71 · Strongly overvalued (−37.7%)
Narrow moat 42/100 · thin data
⟳ Cyclical
Watch Corbion NV for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€38.95 €14.27 Fair Value €16.71 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range €14.27 – €38.95 · fair‑value band €11.49 – €24.47 · the €26.84 price screens above the €16.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow Corbion in your weekly email

Every Wednesday you see whether Corbion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Corbion N.V. provides lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-derived nutritional ingredients in the Netherlands, the United States, Asia, rest of Americas, the rest of Europe, the Middle East, and Africa.

Show moreShow less

It operates in two segments, Functional Ingredients & Solutions, and Health & Nutrition.

The company offers antioxidants, fermentation and preservation ingredients, flavors, fortification, functional blends, and lactic acid lactates and derivatives; AlgaPrime DHA, an omega-3 sourcing product; AlgaVia which develops foods and beverages with reduced saturated fat content; CALFEED, a dry lactic acid source to boost feed intake for swine or poultry; LAFEED that helps feed intake and digestive health; LAFEED Powder that acts as a preservative and acidulate; PURAC DW, provides an acidifier, preservative, and antimicrobial in teat-dip applications for animals; PURAC Pet food; PURASOLV; and PURASOLV EL. It also provides PURASORB polymers for medical and pharmaceutical industries; PURASOLV solvents; PURALACT B3 for resin and coating performance; personal care products, such as ESTERLAC Emulsifiers and Surfactants, GLUCONAL ZN, PURAC BF/P41, PURAC HiPure 90, PURAC UltraPure, PURACAL PP/USP, PURAMEX ZN, PURASAL MOISTXS, PURASAL NH/COS, PURASAL S/HQ60, and PURASOLV EL; and GLUCONAL, PURAC PF, PURACAL, PURAMEX, and PURASAL S/PF. In addition, the company offers food solutions, including acidification, color retention, decontamination, food safety and preservation, freshness and shelf life, health and nutrition, strengthening conditioning and texturizing, and taste and texture; PURASORB R&D; biochemical specialties solutions comprising solvency, antimicrobial, moisturization, and pharma; and Algae ingredients solutions.

The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1903 and is headquartered in Amsterdam, the Netherlands.

Stock analysis

Corbion NV (CRBN) currently trades at €26.84, while our model-based Fair Value estimate is €16.71, 38% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €22.06 per share, and 2 of the 24 models we run sit above the €26.84 price.

Bear case: the Dividend Discount group reads lowest at €5.90, and 22 of the 24 models stay below the price. Data coverage for this calculation is high.

Scenario range: €11.49 (bear) to €24.47 (bull), the price of €26.84 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Basic Materials sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Corbion NV reported revenue of €1.3B in FY2025 versus €1.1B in FY2021, a compound +4.3%/yr. Reported net income was €74.8M in FY2025, compounding −1.1%/yr from FY2021.

Key figures

Market cap €1.6B Small · P/E ratio 25.3 · P/S ratio 1.25 · EPS (TTM) €1.06 · Dividend yield 2.4% · Net margin 5.0% · Return on equity 8.4% · Return on assets (EBIT) 6.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 58% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −38%, CRBN screens cheaper than that median.

Fair Value models

Bear €11.49 Fair Value €16.71 Bull €24.47
Price €26.84 · Downside -37.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.3590 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF €11.49 €16.55 €25.22 77
Growth DCF €12.04 €16.85 €24.47 76
EPV €9.12 €11.06 €12.70 74
All 24 models by family
DCF Models
FCF DCF €11.49 €16.55 €25.22 77
Owner Earnings €8.16 €12.17 €19.06 73
5Y Revenue Exit €11.91 €19.38 €30.27 69
5Y EBITDA Exit €15.15 €24.98 €38.02 72
5Y P/E Exit €10.37 €16.71 €24.34 68
10Y Revenue Exit €11.20 €16.50 €22.18 65
10Y EBITDA Exit €13.45 €19.72 €26.43 67
10Y P/E Exit €10.75 €14.95 €18.92 63
Earnings-Based
Graham-Dodd €8.82 €11.06 €12.54 65
EPV €9.12 €11.06 €12.70 74
Dividend Discount
Gordon GGM €5.16 €5.57 €6.19 67
DDM Multi-Stage €5.16 €6.22 €7.58 65
Multiples
P/E Multiple €16.54 €22.06 €27.57 63
P/S Multiple €16.54 €22.06 €27.57 58
P/B Multiple €25.50 €34.01 €42.51 55
EV/EBIT €13.65 €20.72 €27.79 65
EV/EBITDA €18.75 €27.52 €36.29 66
EV/Revenue €10.82 €18.70 €26.58 52
Asset-Based
NCAV (Graham) €5.67 €7.59 €11.34 54
Growth DCF
Growth DCF €12.04 €16.85 €24.47 76
Rev-Margin DCF €11.91 €19.80 €29.50 69
Economic Profit
Residual Income €10.96 €11.96 €13.57 74
ROIC Compounder €9.12 €11.06 €12.70 70
Growth Earnings
Growth-Adj P/E €11.78 €16.84 €21.89 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 61/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 47
Are margins and returns getting better?
Cashflow 57
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 72
How calm the share price moves, does not count
Price momentum 83
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 93
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.0%
Dividend (yield on the price)2.4%
Per share before 2009divided by the spin-off factor 1.0476
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.0% vs −1.7%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +10.1% a year for the price and +1.5% for the forecasts.
Forecast 2026 (sales)+2.3%
Forecast 2027 (sales)+4.5%
Projected 2028 (sales)+4.2%
Projected 2029 (sales)+3.9%
Projected 2030 (sales)+3.5%

CRBN screens overvalued: fair value 38% below the price. Compare with Linde plc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (78 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Corbion NV with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 727 stocks

Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 61 · Top 25%
Fair Value upside −37.7% · Below median
Profitability
Return on equity (12 months) 8.4% · Above median
Return on assets 5.3% · Above median
Net margin (12 months) 5.0% · Below median
Operating margin (12 months) 7.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) −2.2% · Bottom 25%
Dividend yield (12 months) 2.4% · Above median
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (12 months) 25.3× · Pricier than median
P/B 2.11× · Pricier than median
P/S (12 months) 1.25× · Cheaper than median
Price / free cash flow (fiscal year) 16.9× · Cheaper than median
EV/EBITDA 10.8× · Cheaper than median
PEG 1.26× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 67
PAST (return on equity)34 · sector 26
HEALTH (low debt)79 · sector 95
DIVIDEND (yield)48 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nan Ya Plastics Corporation 1303 239.50 TWD 383.20 TWD +60% vs CRBN
Wanhua Chemical Group 600309 ¥72.65 ¥68.03 −6% vs CRBN
Linde plc LIN $515.25 $446.62 −13% vs CRBN
PPG Industries, Inc PPG $122.38 $77.68 −37% vs CRBN
DSM-Firmenich AG DSFIR CHF 100.50 CHF 57.70 −43% vs CRBN
The Sherwin-Williams Company SHW $344.10 $146.37 −57% vs CRBN
Givaudan SA GIVN CHF 4,054 CHF 1,554 −62% vs CRBN
EMS-CHEMIE HOLDING AG EMSN CHF 848.50 CHF 284.63 −66% vs CRBN
Ecolab Inc ECL $300.68 $96.56 −68% vs CRBN
Air Products and Chemicals, Inc APD $304.84 $82.92 −73% vs CRBN

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Corbion NV: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Corbion NV Fair Value". https://www.fairvalue-calculator.com/stock/CRBN

Frequently asked questions

Is Corbion NV (CRBN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of €16.71 versus a price of €26.84, about 38% lower (overvalued).
What is the fair value of CRBN?
Our model-based fair value for Corbion NV is €16.71 (as of Nov 8, 2026), built from audited fundamentals. The current price: €26.84.
What is the quality score of CRBN?
Corbion NV has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corbion NV (CRBN)?
Our model-based price target is the fair value of €16.71 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario €11.49, optimistic scenario €24.47. It is a calculation from audited fundamentals, not an analyst target.
What is the Corbion NV stock forecast for 2026?
Our models put fair value at €16.71, about 38% lower versus a price of €26.84 (overvalued). Cautious scenario €11.49, optimistic scenario €24.47. The calculation is refreshed regularly with new filings.
What is the revenue of Corbion NV (CRBN)?
Corbion NV reported trailing-twelve-month revenue of about €1.3B (latest available figure, as of Nov 8, 2026).
Does Corbion NV pay a dividend?
Corbion NV currently shows a dividend yield of 2.38% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Corbion NV (CRBN) and when is the ex-dividend date?
Corbion NV pays a dividend of €0.64 per share a year, a dividend yield of 2.4%. The last ex-dividend date was May 15, 2026. A dividend has been paid every year since at least 1991. The payout ratio is 60.4% of earnings. Free cash flow covers the dividend 2.51 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Corbion NV (CRBN)?
For today's price to be fair in a discounted-cash-flow model, Corbion NV would have to grow free cash flow by +12.5 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.1 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of CRBN use?
Our models discount Corbion NV at 10.6 %: a base by market capitalisation (small), damped by beta 0.87, country premium for Netherlands. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Corbion NV that is +12.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Corbion NV (CRBN) delivered so far?
Over the past 5 years revenue at Corbion NV grew +5.1 % a year. The price currently implies free-cash-flow growth of +12.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Corbion NV (CRBN) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Corbion NV (+12.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Corbion NV (CRBN)?
The free-cash-flow yield on the price is 5.91 %: that much free cash flow Corbion NV produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Corbion NV (CRBN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corbion NV it is €16.71 per share (as of Nov 8, 2026), against a price of €26.84. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Corbion NV stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CRBN trades above its calculated fair value: price €26.84, fair value €16.71, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRBN?
No. The price is what the market pays today (€26.84); the fair value is what the company's own numbers justify (€16.71). For Corbion NV the two are €10.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Corbion NV worth?
The market values Corbion NV at about €1.6B (market capitalisation, as of Nov 8, 2026). Per share that is €26.84; our models calculate a fair value of €16.71 per share.
What do the bullish and bearish scenarios say about CRBN?
Our models span a range for Corbion NV: cautious scenario €11.49, base €16.71, optimistic €24.47 per share (as of Nov 8, 2026, price €26.84). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CRBN?
Corbion NV trades at a price-to-earnings ratio of 25.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €16.71 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 19.9. Other multiples: PEG 1.3, P/B 2.1, P/S 1.3, EV/EBITDA 10.8.
What is the PEG ratio of CRBN?
The PEG ratio of Corbion NV is 1.26 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Corbion NV (CRBN)?
Balance-sheet figures for Corbion NV (as of Nov 8, 2026): return on equity 8.4%, debt of 0.42 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is CRBN from its 52-week high?
Corbion NV trades at €26.84, about 3% below its 52-week high of €27.56 and 58% above the low of €17.03 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €16.71 is for.
Which stocks are comparable to Corbion NV?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corbion NV stock attractive at the current price?
The data as of Nov 8, 2026: price €26.84, calculated fair value €16.71 (−38%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRBN calculated?
We run Corbion NV through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €16.71 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Corbion NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corbion NV (CRBN)?
The closing price on Nov 6, 2026 was €26.84. Our model-based fair value is €16.71, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corbion NV right now?
The price sits above even our optimistic bull case (€24.47). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€11.49 to €24.47) leaves room in how you read the outcome.
Where does the earnings growth of Corbion NV (CRBN) come from?
Earnings per share at Corbion NV grew +2.7 % a year from 2015 to 2025. Broken into its drivers: revenue per share +4.7 %, EBIT margin −6.7 %, tax rate +0.5 %, residual (interest, one-offs) +4.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Corbion NV

How large is the market capitalisation of Corbion NV (CRBN)?
The market capitalisation of Corbion NV is €1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Corbion NV (CRBN)?
The price-to-sales ratio of Corbion NV is 1.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Corbion NV (CRBN)?
Earnings per share at Corbion NV are €1.06 (price ÷ EPS = P/E 25.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Corbion NV (CRBN)?
The dividend yield of Corbion NV is 2.4% (payout 60.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Corbion NV (CRBN)?
The net margin of Corbion NV is 5.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Corbion NV (CRBN)?
The return on equity (ROE) of Corbion NV is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corbion NV (CRBN)?
On an EBIT basis the return on assets of Corbion NV is 6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Corbion NV (CRBN)?
The operating margin of Corbion NV is 7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Corbion NV (CRBN)?
Revenue at Corbion NV is growing −2.2% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Corbion NV (CRBN)?
Earnings per share at Corbion NV are growing −29.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Corbion NV (CRBN) carry?
The net debt of Corbion NV is €436M (fiscal year 2025, ≈ 4.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Corbion NV in the live analysis

One click puts Corbion NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.